ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Evaluation of the sensitivity of the immuno-PET PET / CT pretargeted with the bispecific
anti-CEA x anti-HSG TF2 antibody and IMP-288 peptide labeled with Gallium-68 for imaging
potential candidate patients for surgery of local resection of one or more metastases at
diagnosis or during relapse CCR expressing CEA.